Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
Stopped Roche stopped thr peoduction of one of the study product.
Conditions
- Metastatic Cancer Lung
- Advanced Lung Cancer
- CBNPC Cancer
Interventions
- DRUG: Atezolizumab 1200 mg IV
- DRUG: Tiragolumab 600 mg IV
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators